In NSCLC, around 1.9% of patients have PD-L1 gene amplification and approximately 8.2% of them exhibit PD-L1 gene amplification at 9p24.1 which is associated with the JAK-STAT pathway and concurrent amplification of the JAK2 gene (32–34). This evidence concerns the gene SOAT1 and non-small cell lung carcinoma.